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Peste des Petites Ruminants Virus (PPRV) is a highly contagious disease affecting small ruminants in Africa 
and Asian countries, with negative/significant economic impact. Aiming to eradicate the disease, targeted by the 
Food and Agriculture Organization for 2030, a novel and scalable PPRV vaccine production process is clearly 
needed. Built upon work previously done at iBET, a new production process is herein proposed using Vero cells 
growing on microcarriers, serum-free medium (SFM) and stirred-tank bioreactors (STB). This includes a new 
method for cells detachment from microcarriers, and perfusion culture for reducing turnaround time. 
 
The PPRV vaccine production process was developed in the 2L BIOSTAT® DCU-3 and the 20L BIOSTAT® 
Cplus STB (both from Sartorius) using Nigeria 75/1 strain. Engineering correlations (energy dissipation rate, 
shear stress and Kolmogorov Eddy size) were used to optimize culture conditions in the 2 L STB and to scale-
up the process to the 20 L STB. Vero cells were adapted to grow in ProVeroTM-1 SFM (Sartorius). A new 
enzymatic and mechanical method for in situ cell detachment from microcarriers was designed. Perfusion was 
evaluated in the 2 L STB (equipped with internal spin-filter) in order to reduce seed-train preparation time. PPRV 
were clarified using depth filtration (Sartopure PP3, Sartorius). Process scalability was validated in the 20 L 
STB. 
 
Vero cells were adapted to ProVeroTM-1 SFM, reaching growth rates similar to serum-containing cultures (0.03 
h-1). The new in situ cell detachment method was successfully implemented, with yields above 80%. A two-fold 
increase in maximum cell concentration was obtained using perfusion when compared to batch culture. 
Combining perfusion with the new in situ cell detachment method enabled the scale-up to 20 L STB directly from 
a 2 L STB, surpassing the need for a mid-scale platform and thus reducing seed-train preparation time. 
Infectious PPRV titers increase over culture time in both 2 L and 20 L STBs, reaching maximum values of 4.5-
4.9x106 TCID50/mL at day 4-5 post-infection. The potential of depth filtration for PPRV clarification was 
confirmed; comparable PPRV recovery yields after clarification (85-90%) were obtained in both STBs. 
 
Overall, the novel and scalable vaccine production process herein proposed has the potential to assist the 
upcoming PPR Global Eradication Program (PPR GEP), to which iBET already contributes as partner in the 
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